title: Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia.
authors.forename: C
authors.initials: C
authors.lastname: Shustik
authors.forename: A R
authors.initials: AR
authors.lastname: Turner
authors.forename: P
authors.initials: P
authors.lastname: Desjardins
authors.forename: L
authors.initials: L
authors.lastname: Fernandez
authors.forename: S
authors.initials: S
authors.lastname: Rubin
authors.forename: L
authors.initials: L
authors.lastname: Larratt
authors.forename: A M V
authors.initials: AM
authors.lastname: Duncan
authors.forename: D
authors.initials: D
authors.lastname: Rizi
authors.forename: A
authors.initials: A
authors.lastname: Sadura
authors.forename: L
authors.initials: L
authors.lastname: Shepherd
authors.forename: D
authors.initials: D
authors.lastname: Li
authors.forename: L
authors.initials: L
authors.lastname: Rassenti
authors.forename: T
authors.initials: T
authors.lastname: Kipps
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009154:Mutation; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D007143:Immunoglobulin Heavy Chains; D007135:Immunoglobulin Variable Region; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; D014740:Vidarabine; C024352:fludarabine